All In Biotech

Drug Trial Radar · NCT03859219

A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants

A Randomized, Participant-Blind, Investigator-Blind, Placebo-Controlled Study Comparing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Doses of Rozanolixizumab in Japanese, Chinese and Caucasian Healthy-Volunteer Study Participants

Last checked: Nov 20, 2026Latest source record: Sep 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

65

Actual

Start

Mar 18, 2019

Primary completion

Apr 28, 2020

Study completion Apr 28, 2020

Sponsor

Lead sponsor
UCB Biopharma S.P.R.L.UCB
Sponsor type
Industry
First posted
Mar 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of rozanolixizumab in japanese, chinese and caucasian healthy-volunteer study participants.

Conditions

  • Healthy-volunteers

Interventions

  • RozanolixizumabDrug

    * Pharmaceutical form: solution for injection * Route of administration: subcutaneous infusion

  • PlaceboDrug

    * Pharmaceutical form: solution for injection * Route of administration: subcutaneous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse events (TEAEs) from Baseline to Safety Follow-up (SFU) in healthy Japanese study participantsTime frame: From Baseline until Safety Follow-up (up to Week 8)
  2. Treatment-emergent adverse events (TEAEs) from Baseline to Safety Follow-up (SFU) in healthy Chinese study participantsTime frame: From Baseline until Safety Follow-up (up to Week 8)
  3. Maximum observed plasma concentration (Cmax) of rozanolixizumab in healthy Japanese study participantsTime frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours
  4. Maximum observed plasma concentration (Cmax) of rozanolixizumab in healthy Chinese study participantsTime frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours
  5. Time to maximum observed plasma concentration (tmax) of rozanolixizumab in healthy Japanese study participantsTime frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours
  6. Time to maximum observed plasma concentration (tmax) of rozanolixizumab in healthy Chinese study participantsTime frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours
  7. Area under the concentration-time curve from time 0 to time t (AUC(0-t)) of rozanolixizumab in healthy Japanese study participantsTime frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours
  8. Area under the concentration-time curve from time 0 to time t (AUC(0-t)) of rozanolixizumab in healthy Chinese study participantsTime frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UP0060 1

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.